SCHEMBL6154397

SCHEMBL6154397

CN[C@H]1CC[C@H](Nc2cc(OC)c(C(N)=O)cc2Cl)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 2/20 0.49
RET P07949 2/20 0.43
PDGFRB P09619 2/20 0.43
KIT P10721 2/20 0.43
FGFR1 P11362 2/20 0.43
PDGFRA P16234 2/20 0.43
FLT1 P17948 2/20 0.43
FLT4 P35916 2/20 0.43
KDR P35968 2/20 0.43
RIPK2 O43353 1/20 0.43
ERN1 O75460 1/20 0.43
STK10 O94804 1/20 0.43
MAP3K6 O95382 1/20 0.43
ABL1 P00519 1/20 0.43
ESR1 P03372 1/20 0.43
ADORA3 P0DMS8 1/20 0.43
BCR P11274 1/20 0.43
NQO2 P16083 1/20 0.43
TBXA2R P21731 1/20 0.43
FGFR2 P21802 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6154410 1.00 LRRK2 (0.49) LRRK2RETPDGFRBKITFGFR1
SCHEMBL6153878 0.90 ROCK2 (0.52) LRRK2RETPDGFRBKITFGFR1
SCHEMBL6153479 0.90 ROCK2 (0.52) LRRK2RETPDGFRBKITFGFR1
SCHEMBL6153477 0.90 ROCK2 (0.52) LRRK2RETPDGFRBKITFGFR1
SCHEMBL12316370 0.90 CA1 (0.51) LRRK2DRD4HTR4CA1CA2
SCHEMBL6153305 0.88 CA1 (0.47) LRRK2RETPDGFRBKITFGFR1
SCHEMBL6153343 0.88 CA1 (0.47) LRRK2RETPDGFRBKITFGFR1
SCHEMBL6154617 0.87 HTT (0.44) LRRK2RETPDGFRBKITFGFR1
SCHEMBL6156118 0.87 LRRK2 (0.44) LRRK2RETPDGFRBKITFGFR1
SCHEMBL6154619 0.87 HTT (0.44) LRRK2RETPDGFRBKITFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050182040-A1 Benzamide derivatives DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-18 US disclosed
EP-1500643-A1 BENZAMIDE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2005-01-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182040-A1 Benzamide derivatives ROCK1, ROCK2, NHERF1 LRRK2 3177/4885RET 903/4885PDGFRB 978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.